Corcept Therapeutics | CORT - Equity Capital And Reserves


Corcept Therapeutics reported $705.78M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Corcept Therapeutics USD 705.78M 67.79M Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 671.98M 18.08M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
TG Therapeutics USD 604.08M 20.95M Jun/2026